Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation
Sponsor: Revolution Medicines, Inc.
A observational or N/A phase clinical study on Lung Cancer and MTAP Deletion, this trial is actively recruiting participants. The trial is conducted by Revolution Medicines, Inc. and has accumulated 8 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel.
For the RAS inhibitor arms, the study will be conducted in patients with MTAP loss and RAS mutant metastatic pancreatic adenocarcinoma (PDAC) or locally advanced or metastatic non-small cell lung cancer (NSCLC). For the chemotherapy specific arms, the study will be conducted in patients with MTAP loss locally advanced or metastatic PDAC. The entire study (all arms) will be conducted in 2 parts: Phase 1 (dose escalation) and Phase 2 (dose expansion).
Individual Arms in the dose expansion phase may open once the MTD and/or RD(s) has been determined for the corresponding combination in the dose escalation phase of the study.
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel.
For the RAS inhibitor arms, the study will be conducted in patients with MTAP loss and RAS mutant metastatic pancreatic adenocarcinoma (PDAC) or locally advanced or metastatic non-small cell lung cancer (NSCLC). For the chemotherapy specific arms, the study will be conducted in patients with MTAP loss locally advanced or metastatic PDAC. The entire study (all arms) will be conducted in 2 parts: Phase 1 (dose escalation) and Phase 2 (dose expansion).
Individual Arms in the dose expansion phase may open once the MTD and/or RD(s) has been determined for the corresponding combination in the dose escalation phase of the study.
Status Flow
Change History
8 versions recorded-
Apr 23, 2026 — Present [daily]
Recruiting
Phase: PHASE1/PHASE2 → None
-
Jan 2026 — Apr 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2025 — Dec 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 3 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Jul 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
First recorded
Eligibility Summary
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.
Contact Information
- Revolution Medicines, Inc.
- Tango Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .